Literature DB >> 20473035

Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer.

Florian Hohla1, Andrew V Schally.   

Abstract

Gastrin-releasing peptide (GRP), the mammalian bombesin (BN), appears to be involved in the growth of several neoplasms. BN/GRP receptors (BN/GRP-Rs) are expressed in a variety of cancer cells and have limited distribution in normal human tissue. Thus inhibition of BN/GRP-Rs represents an attractive target for pharmacological treatment of some human malignancies. This review will focus on intracellular signaling pathways which have been characterized to mediate BN/GRP-dependent receptor biological effects as well as on various approaches to target BN/GRP-Rs for therapeutic and diagnostic interventions in human malignancies.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20473035     DOI： 10.4161/cc.9.9.11347

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


  27 in total

Review 1.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

Review 2.  GPCRs and cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

3.  Correlation of the Ga-68-bombesin analog Ga-68-BZH3 with receptors expression in gliomas as measured by quantitative dynamic positron emission tomography (dPET) and gene arrays.

Authors:  Ludwig G Strauss; Dirk Koczan; Marcel Seiz; Jochen Tuettenberg; Kirsten Schmieder; Leyun Pan; Caixia Cheng; Antonia Dimitrakopoulou-Strauss
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

Review 4.  Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Authors:  Paola Moreno; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2016-03-28       Impact factor: 6.902

Review 5.  Peptide receptors as cancer drug targets.

Authors:  Terry W Moody
Journal:  Ann N Y Acad Sci       Date:  2019-05-10       Impact factor: 5.691

6.  Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.

Authors:  Ferenc G Rick; Andrew Abi-Chaker; Luca Szalontay; Roberto Perez; Miklos Jaszberenyi; Arumugam R Jayakumar; Nagarajarao Shamaladevi; Karoly Szepeshazi; Irving Vidaurre; Gabor Halmos; Awtar Krishan; Norman L Block; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

Review 7.  Prostate cancer relevant antigens and enzymes for targeted drug delivery.

Authors:  Ashutosh Barve; Wei Jin; Kun Cheng
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

Review 8.  Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.

Authors:  Florian Hohla; Thomas Winder; Richard Greil; Ferenc G Rick; Norman L Block; Andrew V Schally
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 9.  Targeting GRPR in urological cancers--from basic research to clinical application.

Authors:  Rosalba Mansi; Achim Fleischmann; Helmut R Mäcke; Jean C Reubi
Journal:  Nat Rev Urol       Date:  2013-03-19       Impact factor: 14.432

10.  A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.

Authors:  Paola Moreno; Samuel A Mantey; Suk H Lee; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Peptides       Date:  2018-02-02       Impact factor: 3.750
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.